SynAct Pharma’s FY25 results reflect a year of solid execution, highlighted by the continued advance...
Efter den misslyckade satsningen mot elbilar återgår CTEK till kärnaffären: premiumladdare för lågvo...
Nettoomsättningen under det fjärde kvartalet 2025 uppgick till 6,4 MSEK (2,4), motsvarande en tillvä...
Acuvi redovisade ökad nettoomsättning och försämrat rörelseresultat i det fjärde kvartalet.
Redeye returns with positive estimate revisions on the back of AAC's Q4 report that fell short of ou...
CEO Michael-Robin Witt answers questions about the Q4 report and discusses other recent news with Vä...
Redeye comments on SynAct Pharma's directed share issue of gross cSEK52m.
Redeye returns with an update following AlzeCure’s Q4 2025 earnings release.
* Professor Hall comments on the XSTEM study results * In discussions with investigator-initiated st...
Redeye has updated its estimates and valuation following Physitrack’s Q4 2025 report.
Vaxxa levererade omsättningstillväxt i det fjärde kvartalet.
Nettoomsättningen i Q4’25 uppgick till 152,8 MNOK (80,1), motsvarande en tillväxt om 90,8 %.
Today, trading in Train Alliance shares has been temporarily suspended.
Gofore just announced (via a stock exchange release) it has been chosen as the priority supplier for...
Redeye raises its forecasts and Base Case slightly following the acquisition of JOWO, strengthening ...
Redeye provides an update following MindArk’s Q4 2025 report, which showed weaker than anticipated s...
Redeye positively views the FDA approval of extended labelling for Nevisense, allowing measurements ...
CapMan just announced its second exit from its Infra I fund (2020).
Nokian Panimo delivered a solid H2 in line with expectations, entering 2026 with a record product la...
Xplora reported record results in the Q4 report, and it reported gross profit of NOK 312m, 7% higher...
